Compare AFB & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AFB | ALLO |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.9M | 252.9M |
| IPO Year | N/A | 2018 |
| Metric | AFB | ALLO |
|---|---|---|
| Price | $10.97 | $1.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $8.27 |
| AVG Volume (30 Days) | 74.0K | ★ 4.2M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 3.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.95 | $0.86 |
| 52 Week High | $11.05 | $3.78 |
| Indicator | AFB | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 61.65 | 59.70 |
| Support Level | $10.83 | $1.62 |
| Resistance Level | $10.95 | $1.88 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 89.66 | 56.41 |
Alliancebernstein National Muni Inc Fd is a diversified, closed-end management investment company. It seeks to provide high current income exempt from regular federal income tax by investing substantially all of its net assets in municipal securities that pay interest that is exempt from federal income tax.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.